Quick Answer
Lineage Cell Therapeutics, Inc. reported Operating Income Loss of -$36.62 million for the year ending 2025.
- Lineage Cell Therapeutics, Inc. showed a decrease of -70.5% in Operating Income Loss from 2024 to 2025.
- This data is from Lineage Cell Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2014: -$14.41 million | Q1 2015: -$13.50 million | Q2 2015: -$13.50 million | Q3 2015: -$17.10 million | Q4 2015: -$21.71 million | Q1 2016: -$23.76 million | Q2 2016: -$14.40 million | Q3 2016: -$9.56 million | Q4 2016: -$11.25 million | Q1 2017: -$11.26 million | Q2 2017: -$8.56 million | Q3 2017: -$9.51 million | Q4 2017: -$9.56 million | Q1 2018: -$12.19 million | Q2 2018: -$9.14 million | Q3 2018: -$10.36 million | Q4 2018: -$10.11 million | Q1 2019: -$12.76 million | Q2 2019: -$10.82 million | Q3 2019: -$8.42 million | Q4 2019: -$6.87 million | Q1 2020: -$7.44 million | Q2 2020: -$6.40 million | Q3 2020: -$6.73 million | Q4 2020: -$5.88 million | Q1 2021: -$7.05 million | Q2 2021: -$7.08 million | Q3 2021: -$6.84 million | Q4 2021: -$28.24 million | Q1 2022: -$6.40 million | Q2 2022: -$4.23 million | Q3 2022: -$5.25 million | Q4 2022: -$6.64 million | Q1 2023: -$6.64 million | Q2 2023: -$5.02 million | Q3 2023: -$6.71 million | Q4 2023: -$6.36 million | Q1 2024: -$6.66 million | Q2 2024: -$5.87 million | Q3 2024: -$3.84 million | Q1 2025: -$6.51 million | Q2 2025: -$19.78 million | Q3 2025: -$3.79 million.
- Over the full 17 years of available data (2009 to 2025), Lineage Cell Therapeutics, Inc.'s Operating Income Loss has declined by 940.2%.
- Historical annual values: Fiscal year 2025: -$36.62 million | Fiscal year 2024: -$21.48 million | Fiscal year 2023: -$24.73 million | Fiscal year 2022: -$22.52 million | Fiscal year 2021: -$49.21 million | Fiscal year 2020: -$26.45 million | Fiscal year 2019: -$38.88 million | Fiscal year 2018: -$41.80 million | Fiscal year 2017: -$38.90 million | Fiscal year 2016: -$58.97 million | Fiscal year 2015: -$65.81 million | Fiscal year 2014: -$50.68 million | Fiscal year 2013: -$55.99 million | Fiscal year 2012: -$25.00 million | Fiscal year 2011: -$18.69 million | Fiscal year 2010: -$9.85 million | Fiscal year 2009: -$3.52 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: